ADIM
BMY icon

Alpha DNA Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Alpha DNA Investment Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-665
Closed -$41K – 165
2021
Q1 		$41K Buy
665
+132
+25% +$8.21K 0.05% 201
2020
Q4 		$33K Buy
+533
New +$32.8K 0.04% 211

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Alpha DNA Investment Management's BMY Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Bristol-Myers Squibb (BMY) in Q2 2021, closing a stake of 665 shares — an estimated $41K sold.

Alpha DNA Investment Management first reported a position in BMY in Q4 2020 and held it in 2 quarters. The position peaked at $41K in Q1 2021. 2,369 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Bristol-Myers Squibb position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 665 Bristol-Myers Squibb shares in Q2 2021, an estimated $41K.
  • Alpha DNA Investment Management first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Bristol-Myers Squibb position peaked at $41K in Q1 2021.
  • 2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.